

**Canadian Task Force on Preventive Health Care** ~ **Public Record of Meeting** June 6 & 7 2022, In-person meeting

CTFPHC Chairs:	Task Force Members:	<b>Additional Participants:</b>	ERSC	КТ
Brenda Wilson (Interim Co-Chair)	Roland Grad	РНАС	Dria Bennett	Sharon Straus
Roland Grad (Interim Co-Chair)	Brenda Wilson	Anne Brasset-Latulippe	Melissa Brouwers	Robyn Beckett
	Scott Klarenbach	Chantelle Garritty	Lindsay Gaudet	Harleen Buttar
<b>Task Force Administrators</b>	Ahmed Abou-Setta	Casey Gray	Lisa Hartling	Arthana Chandraraj
Daniela Cortinovis	Eddy Lang	Wen Qiu Huang	Julian Little	Fatiah De Matas
Théodora Lufitha	Emily McDonald	Heather Limburg	David Moher	Sarah Deshpande
	Donna Reynolds	Maurica Maher	Jennifer Pillay	Mohamed Hassan
	Henry Siu	Chantal Plante	Nicole Shaver	
	Guylène Thériault	Melissa Subnath		Communications
		Laure Tessier	<b>Task Force Fellows</b>	Kim Barnhardt
		Gregory Traversy	Anthony Train	
		Julie Wu	Richard Henry	Guests
				Mike Allan
		JGH		Tina Korownyk
		Daniela Cortinovis	Task Force Alumni	
		Théodora Lufitha	Brett Thombs	
	Regrets: Chantal Plante (PHAC)			

# KEY DISCUSSION POINTS / DECISIONS / RECOMMENDATIONS

### **Day One**

# **1. Welcome and Introductions**

The Task Force held its first hybrid meeting in Calgary June 2022. For those who could not be present, the meeting was also broadcasted via videoconference. Dr. Wilson and Dr. Grad opened the meeting and Task Force members approved the agenda. Dr. Wilson provided some brief guidelines on the proceedings of this meeting.

Dr. Wilson went through some housekeeping items such as the COVID-19 protocol for those attending in person. Roundtable introductions were done, and Dr. Wilson welcomed new staff of the Task Force.

The interim co-Chairs thanked everyone for their participation.

# 2. Cervical Cancer

Ms. Pillay and Dr. Reynolds presented updates on the Cervical Cancer guideline.

#### 3. Tobacco

Mr. Traversy presented on the Evidence to Decision (EtD) framework and ensuing recommendations for behavioural interventions for smoking cessation.

# 4. Methods

Dr. Abou-Setta presented an update on the methods manual, the thresholds discussion, along with cancer outcomes.

# 5. CVD/ Hypertension Planning discussion

Dr. Wilson introduced the issue and prepared the group for the upcoming decisions regarding cardiovascular disease (CVD) and hypertension topics.

#### **ACTION ITEMS**

### KEY DISCUSSION POINTS / DECISIONS / RECOMMENDATIONS

#### 6. Knowledge Translation (KT) Update

Ms. Beckett and Ms. Buttar provided updates on recent KT activities and initiatives. This update included information on recently published and upcoming guidelines, new and upcoming KT tools, dissemination activities, Task Force projects, TFPAN (lesson learned and changes to the methods), recommendations from the Task Force annual evaluation as well a review of the KT budget and related priorities.

# 7. CVD

Dr. Allan and Dr. Korownyk (PEER Group) presented an overview PEER's mandate, their guideline work and the current update to their lipid guideline.

### 8. Communication Update

Ms. Barnhardt presented an update on the recent work of the Communications team and their ongoing initiatives specifically on the PPP Depression communications approach.

#### 9. Lung Cancer

Dr. Klarenbach presented an update and discussed the draft objectives of using OncoSim (not seeking approval).

# Day Two

# **10. CVD Decisions**

Dr. Grad led a discussion to seek tentative decision on CVD in light of the PEER group's presentation.

# 11. Hypertension

Dr. Wilson and Ms. Garitty presented on the KQs of the Hypertension guideline.

#### **ACTION ITEMS**

# KEY DISCUSSION POINTS / DECISIONS / RECOMMENDATIONS

## 12. Topics

Ms. Limburg presented on the Topics, specifically seeking TF approval of Topic WGs recommendation to send AAA for confirmation and seeking confirmation on the final decision on the 2023/24 topic short list. Ms. Limburg also provided an update on the annual surveillance (Prevention plus) and the next steps for the WG.

# 13. Verbal Updates on Guidelines

The guideline Working Group Chairs provided brief updates for the following guidelines: Prostate Cancer Screening, Depression (PPP, adult and child/adolescent), Fragility Fractures, Opioids, and Equity.

# 11. Next Steps and Adjournment

Dr. Grad thanked everyone for attending. The June 2022 Task Force hybrid meeting was adjourned.